Physician profile
Arvinder Pal Walia
NPI 1427163617
$2,540,630.31
in general payments reported to CMS, 2019-2025
29 companies · $488K in 2025
The $488K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412K · 2020: $211K · 2021: $259K · 2022: $323K · 2023: $451K · 2024: $397K · 2025: $488K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.0M · Travel and Lodging: $161K · Honoraria: $72K · Consulting Fee: $52K · Food and Beverage: $35K · Education: $15.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,015,859.00 |
| Travel and Lodging | $160,536.24 |
| Honoraria | $72,275.00 |
| Consulting Fee | $52,200.00 |
| Food and Beverage | $35,230.00 |
| Education | $15.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $727,697.44 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $500,777.90 | 2020-2025 | Caplyta |
| Abbvie INC. | $457,388.13 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $264,874.53 | 2019-2025 | Rexulti, Abilify Mycite |
| Allergan, INC. | $223,732.13 | 2019-2021 | |
| Axsome Therapeutics, INC. | $120,547.41 | 2023-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $93,231.93 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Vanda Pharmaceuticals INC. | $49,663.56 | 2019-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $40,060.77 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $23,583.32 | 2019-2025 | Spravato, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $22,231.19 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $6,951.70 | 2019-2021 | |
| Eisai INC. | $4,587.51 | 2020-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,631.02 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $1,350.26 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $802.54 | 2022-2025 | Azstarys |
| Lundbeck LLC | $421.71 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $300.26 | 2022-2024 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $210.72 | 2019-2025 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $131.39 | 2023 | Quviviq |
| Tris Pharma INC | $126.65 | 2024-2025 | Dyanavel Xr |
| Teleflex LLC | $105.00 | 2024 | Urolift |
| Ironshore Pharmaceuticals INC. | $67.26 | 2024 | |
| Bausch Health US, LLC | $62.08 | 2020-2021 | |
| Srs Medical Systems, INC. | $24.04 | 2024 | Urocuff-Dc Disposable, Single, Ct3000 Pro Base Unit |
| Avanir Pharmaceuticals, INC. | $23.42 | 2019 | |
| Shire North American Group INC | $20.54 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.32 | 2025 | Relexxii |
| Merck Sharp & Dohme LLC | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvinder Pal Walia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.